Your browser doesn't support javascript.
loading
Ferroptosis in cancer immunity and immunotherapy: Multifaceted interplay and clinical implications.
Zhai, Xiaoqian; Lin, Yiyun; Zhu, Lingling; Wang, Yuqing; Zhang, Jiabi; Liu, Jiewei; Li, Lu; Lu, Xiaojie.
Afiliación
  • Zhai X; Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China; Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Lin Y; Graduate School of Biomedical Sciences, UT MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Zhu L; Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China; Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Wang Y; Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, United States.
  • Zhang J; Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, United States.
  • Liu J; Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China; Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China. Electronic address: jerry_ljw@163.com.
  • Li L; Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China. Electronic address: windflower1991@vip.163.com.
  • Lu X; Department of General Surgery, Liver Transplantation Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. Electronic address: 189@whu.edu.cn.
Cytokine Growth Factor Rev ; 75: 101-109, 2024 02.
Article en En | MEDLINE | ID: mdl-37658030
Ferroptosis is a type of cell death characterized by iron-dependent phospholipid peroxidation and reactive oxygen species overproduction. Ferroptosis induces immunogenic cell death and elicits anti-tumor immune responses, playing an important role in cancer immunotherapy. Ferroptosis suppression in cancer cells impairs its immunotherapeutic efficacy. To overcome this issue, ferroptosis inducers (FINs) have been combined with other cancer therapies to create an anti-tumor immune microenvironment. However, the ferroptosis-based crosstalk between immune and tumor cells is complex because oxidative products released by ferroptotic tumor cells impair the functions of anti-tumor immune cells, resulting in immunotherapeutic resistance. In the present article, we have reviewed ferroptosis in tumor and immune cells and summarized the crosstalk between ferroptotic tumor cells and the immune microenvironment. Based on the existing literature, we have further discussed future perspectives on opportunities for combining ferroptosis-targeted therapies with cancer immunotherapies.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Ferroptosis / Neoplasias Límite: Humans Idioma: En Revista: Cytokine Growth Factor Rev Asunto de la revista: ALERGIA E IMUNOLOGIA / BIOQUIMICA Año: 2024 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Ferroptosis / Neoplasias Límite: Humans Idioma: En Revista: Cytokine Growth Factor Rev Asunto de la revista: ALERGIA E IMUNOLOGIA / BIOQUIMICA Año: 2024 Tipo del documento: Article País de afiliación: China